USANA Health Sciences - USNA Stock Forecast, Price & News

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, April 26th. Jefferies Financial Group lowered shares of USANA Health Sciences from a "hold" rating to an "underperform" rating and lowered their price objective for the stock from $78.00 to $53.00 in a research report on Thursday, July 7th. Finally, DA Davidson reduced their target price on shares of USANA Health Sciences to $57.00 and set an "outperform" rating for the company in a research report on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $77.33.

USANA Health Sciences Stock Up 0.2 %

USNA traded up $0.17 during trading hours on Friday, hitting $69.16. The stock had a trading volume of 46,296 shares, compared to its average volume of 66,296. USANA Health Sciences has a 1 year low of $63.49 and a 1 year high of $103.95. The company's fifty day simple moving average is $70.54 and its 200 day simple moving average is $77.42. The stock has a market cap of $1.33 billion, a PE ratio of 15.23 and a beta of 0.72.

USANA Health Sciences (NYSE:USNA - Get Rating) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.05). USANA Health Sciences had a net margin of 8.27% and a return on equity of 22.49%. During the same quarter in the prior year, the business posted $1.87 earnings per share. As a group, equities analysts expect that USANA Health Sciences will post 3.98 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other news, insider Brent Neidig sold 1,400 shares of the firm's stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $70.93, for a total value of $99,302.00. Following the completion of the transaction, the insider now directly owns 1,406 shares of the company's stock, valued at $99,727.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Brent Neidig sold 1,400 shares of the company's stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $70.93, for a total transaction of $99,302.00. Following the sale, the insider now directly owns 1,406 shares in the company, valued at $99,727.58. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO G Doug Iiekking sold 1,086 shares of the firm's stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $70.51, for a total transaction of $76,573.86. Following the completion of the transaction, the chief financial officer now owns 1,838 shares of the company's stock, valued at $129,597.38. The disclosure for this sale can be found here. Insiders have sold 3,202 shares of company stock valued at $225,450 in the last 90 days. 0.36% of the stock is currently owned by company insiders.